Welcome to our dedicated page for Sutro Biopharma SEC filings (Ticker: STRO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Parsing a biotech filing packed with antibody-drug conjugate data, clinical trial tables, and collaboration footnotes can feel like decoding another language. Sutro Biopharma’s disclosures are no exception—they weave cell-free manufacturing costs, milestone payments, and pipeline updates into hundreds of pages. That complexity is exactly why this page exists.
Stock Titan’s AI-powered summaries turn dense documents into plain-English insights. Whether you need the Sutro Biopharma annual report 10-K simplified for cash-runway projections or a quick take on a Sutro Biopharma quarterly earnings report 10-Q filing, we surface what matters: R&D spend, collaboration revenue, and clinical milestone timing. Real-time alerts track every Sutro Biopharma Form 4 insider transactions real-time, helping you gauge executive confidence long before the market reacts.
Looking for something specific? Start with these common questions we answer directly on this page:
- “Where can I find Sutro Biopharma insider trading Form 4 transactions?”—all Forms 3, 4, and 5 are indexed with AI tags on option grants and share sales.
- “How do I read the latest 8-K?”—each Sutro Biopharma 8-K material events explained note links straight to trial results, FDA designations, or partnership announcements.
- “What’s new in the proxy?”—our breakdown of the Sutro Biopharma proxy statement executive compensation highlights pay tied to pipeline milestones.
Because filings never stop, neither do we. Expect comprehensive coverage of every submission—10-K, 10-Q, S-1, 8-K, and more—updated the moment EDGAR releases them. Need deeper context? Click any section for Sutro Biopharma earnings report filing analysis or tap the chatbot for understanding Sutro Biopharma SEC documents with AI. No spreadsheets to build, no jargon to untangle—just the data that drives decisions.
Monitor Sutro Biopharma executive stock transactions Form 4, compare quarter-over-quarter R&D trends, or export pipeline metrics for your model. Complex science, clear filings—delivered in seconds.
Hans-Peter Gerber, Chief Scientific Officer of Sutro Biopharma, acquired equity and vested awards on 09/18/2025. The Form 4 shows 37,500 restricted stock units (RSUs) were recorded as acquired and will settle into common stock; each RSU converts to one share on settlement. Following the transactions, Mr. Gerber beneficially owned 75,000 shares of common stock. Additionally, the issuer withheld 13,417 shares
David Pauling, Chief Administrative Officer and General Counsel of Sutro BioPharma, Inc. (STRO), amended his Form 3 to correct the number of shares he beneficially owns. The filing reports 56,733 shares of common stock held directly. The amendment notes the original Form 3 filed on April 8, 2025 misstated the total and is otherwise unchanged. The event date requiring the statement is 04/04/2025, and the amended Form 3/A is signed by Mr. Pauling on 09/12/2025.
Barbara Leyman, Chief Business Officer of Sutro Biopharma, reported changes in her holdings on Form 4. She received 25,000 restricted stock units (RSUs) on 07/08/2025 that vest in four equal annual installments beginning 07/08/2025, and those RSUs convert to common stock upon settlement. Following the reported transactions, she beneficially owns 75,000 RSUs. Separately, 8,944 shares of common stock were withheld by the issuer to satisfy tax withholding related to a net settlement of RSUs; this withholding is not a sale by the reporting person. After the withholding and the reported acquisition, she directly beneficially owns 16,056 shares of common stock.
Jane Chung, Chief Executive Officer and Director of Sutro Biopharma, Inc. (STRO), reported insider activity on Form 4 dated 08/26/2025 covering transactions with an earliest date of 08/09/2025. The filing shows the vesting of 18,750 restricted stock units (RSUs) that settled into 18,750 shares of common stock (transaction code M), increasing her beneficial ownership to 117,058 shares. The issuer withheld 6,708 shares
The filers RA Capital Management, L.P., RA Capital Healthcare Fund, L.P., and individuals Peter Kolchinsky and Rajeev Shah submitted an amendment to Schedule 13G for Sutro Biopharma, Inc. (CUSIP 869367102) reporting ownership information as of June 30, 2025. The filing states that each reporting person beneficially owns 0.00 shares and holds 0.0% of the class. The filers expressly disclaim being a group and identify their principal business address as c/o RA Capital Management, L.P., 200 Berkeley Street, 18th Floor, Boston, MA 02116. The filing includes a joint filing agreement incorporated by reference.
Suvretta Capital Management, Averill Master Fund and Aaron Cowen filed an amended Schedule 13G reporting shared beneficial ownership of Sutro Biopharma common stock equal to approximately 6.49 million shares for Suvretta/Cowen and 6.46 million shares for Averill, each representing 7.7% of the class. The filing shows no sole voting or dispositive power and instead reports shared voting and dispositive power for the reported shares. The filing states these securities are directly owned by advisory clients of Suvretta and that, other than Averill, no advisory client is deemed to beneficially own more than 5% of the class. The reporting persons disclaim beneficial ownership except for pecuniary interests and certify the holdings were not acquired to change or influence control of the issuer.
FAQ
What is the current stock price of Sutro Biopharma (STRO)?
What is the market cap of Sutro Biopharma (STRO)?
